Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer

Status Terminated

Clinical Trial Summary

The purpose of this project is to examine whether treatment with vandetanib has an effect on the tumor cells in breast cancer by examining tissue markers.

Clinical Trial Description

The purpose of this research study is to test whether vandetanib has an effect on tumor growth markers. Vandetanib is not approved by the FDA for use in treating breast cancer. This study will compare vandetanib to a placebo. The proposed study is designed to determine the change in Ki-67 expression on paired breast cancer samples obtained before and after treatment with vandetanib. Other tumor markers including RET, TUNEL and phosphorylation specific levels of ERK1/2, AKT and mTOR will also be assessed on the paired samples. Those who have a core biopsy of the breast which demonstrates invasive breast cancer and requires surgical excision of the lesion will be eligible for inclusion in the study. The tyrosine kinase inhibitor, vandetanib 300 mg, will be given once a day for 7-14 days prior to surgery. Following surgery, tissue markers would be analyzed on each of the paired samples, allowing for rapid assessment of in vivo response to TKI treatment. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01934335
Study type	Interventional
Source	University of Iowa
Contact
Status	Terminated
Phase	Phase 2
Start date	October 2013
Completion date	December 21, 2018

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03595592` - Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer	Phase 3
Recruiting	`NCT05383196` - Onvansertib + Paclitaxel In TNBC	Phase 1/Phase 2
Recruiting	`NCT06158217` - Effect of Ultrasound Combined With Microbubbles on Blood Perfusion in Invasive Breast Cancer
Active, not recruiting	`NCT04448886` - Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC	Phase 2
Completed	`NCT02773784` - Comparison of CNB and Surgical Specimens for ER, PgR, HER2 Status and Ki67 Index in Invasive Breast Cancer.
Recruiting	`NCT01509781` - Suction Drain Versus the Use of Adaptive Skin Sutures After Mastectomy ± Axillary Lymphadenectomy; a Prospective Randomised Study	Phase 3
Completed	`NCT04478669` - Digital Breast Tomosynthesis (DBT) to Improve Assessment of Resection Margins in Invasive Breast Cancer
Recruiting	`NCT04553770` - Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer	Phase 2
Recruiting	`NCT04677816` - Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients	Phase 2
Completed	`NCT00507611` - Axillary Lymph Node Status After Completion of Preoperative Neoadjuvant Systemic Chemotherapy in Patients	N/A
Completed	`NCT00581750` - Molecular Genetic Basis of Invasive Breast Cancer Risk Associated With Lobular Carcinoma in Situ
Completed	`NCT03304171` - Overall Diet Quality and Breast Cancer Risk	N/A
Completed	`NCT03709186` - Radiomic Markers for Breast Cancer Metastasis and Treatment Response Using MRI
Terminated	`NCT03361800` - Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC	Early Phase 1
Recruiting	`NCT04648904` - Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer	Early Phase 1
Recruiting	`NCT06328465` - fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases	N/A
Active, not recruiting	`NCT03109522` - Axillary Reverse Mapping (ARM) Technique	N/A
Recruiting	`NCT03987555` - Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
Recruiting	`NCT03497702` - Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer	Phase 2
Recruiting	`NCT05795101` - TRUDI: TDXD+Durva in HER2+/Low IBC	Phase 2